# First ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF.

*biotech · news · 2026-05-05 · The Manila Times*

## Key points

- AXPAXLI achieved the first successful superiority in a Phase 3 wet AMD trial over aflibercept.
- Ocular plans to submit an NDA for AXPAXLI using the 505(b)(2) pathway to potentially shorten review.
- SOL-R Phase 3 non-inferiority trial for wet AMD completed enrollment ahead of target, with data in 1Q 2027.
- The SOL-X extension trial began enrolling, assessing 3-year long-term safety and disease modification potential for AXPAXLI.
- Ocular's cash runway, at $666.7 million as of March 31, 2026, is expected to last into 2028.

**Companies:** Ocular Therapeutix, Inc.
**Countries:** United States, Argentina, India, Australia

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/05/tmt-newswire/globenewswire/ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-highlights/2335850)

---

Canonical: https://newsio.io/n/65afb765-4363-4146-b91a-3c304f694855/first-ever-successful-wet-amd-superiority-trial-comparing-a-novel-investigative
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works